Background
==========

Eight distinct genotypes (A to H) of hepatitis B virus (HBV) have been identified, and this classification is based on the distance of the nucleotide sequence from the viral genome of 8% or greater \[[@B1],[@B2]\]. These genotypes also have a distinct geographical distribution, while genotypes B and C are more common in China. Since genotypes of HBV influence liver disease progression and response to antiviral therapy in HBV-infected patients, several methods have been developed for genotyping of HBV strains \[[@B3]\], these include sequence analysis; microarray (DNA-Chip) \[[@B4],[@B5]\]; reverse hybridization \[[@B6]\]; restriction fragment length polymorphism (RFLP) \[[@B7]\]; serological assays and genotype-specific PCR assays \[[@B8],[@B9]\]. These techniques have the disadvantage that they are based on specific hybridization of HBV DNA, and nucleotide changes can interfere with this process and subsequent sequence analysis. For example, RFLP and multiple PCR methods might give wrong results even for a single base mutation. Serological assay has a low cost and does not rely on PCR amplification, but it is still subjected to the effects of specific base mutation. INNO-LiPA HBV genotyping assay has the limitation of high cost, and also its likelihood to be affected by the specific binding site mutant gene \[[@B10],[@B14]\]. Sequence analysis is definitely the most accurate method and not subject to these constraints, but it is also the most labor intensive technique and needs nested PCR to increase the sensitivity.

As we all know, there are several antiviral therapies\--such as interferon; pegylated interferon or nucleotide/nucleoside analogs\--widely used to treat HBV infection. None of these therapies can eradicate HBV infection and all often induce drug-resistant mutants. As a result, HBV genotyping and the detection of mutations that confer drug resistance help select an appropriate treatment strategy and monitor the treatment. However, there are a limited number of methods that enable simultaneous genotyping and mutation detection. In this study, we used the partial S-gene sequencing using common PCR to genotype HBV, which is simpler and more sensitive compared with the S-gene sequencing.

Partial S-gene sequencing means sequencing part of the S gene from 370 nt to 861 nt. This part of the S gene we chose is relatively conserved and has many drug-resistant mutant sites, so it could be used in both HBV genotyping and in analysis of HBV drug resistant mutation.

Results and discussion
======================

Phylogenetic tree analysis
--------------------------

First, phylogenetic tree analysis was used for testing the possibility of HBV genotyping using partial S gene sequencing. Reference sequences from 32 HBV genomes of eight different genotypes were used (shown as Table [1](#T1){ref-type="table"}). Software MEGA4 was used to analyze these genomes to get the phylogenetic trees of genome sequencing; S gene sequencing and partial S gene sequencing respectively. All these sequences could be genotyped successfully by partial S gene sequencing. The results of phylogenetic tree analysis indicated that the partial S gene sequencing had nearly the same phylogenetic tree as that of the S gene sequencing (shown as Figure [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}).

###### 

Reference sequences for genotyping

  ------------ ------------- ------------- ------------- ------------- ------------
  Genotype A   AM282986      gi_59418      gi_1155012    gi_15419837   gi_5114084
  Genotype B   gi_21280301   gi_221497     gi_221498     gi_4323201    gi_6063442
  Genotype C   gi_13365548   gi_22415734   gi_6063452    NC_003977     gi_3582357
  Genotype D   gi_329640     gi_736003     gi_329667     gi_62280      gi_59439
  Genotype E   gi_452617     gi_6691492                                
  Genotype F   gi_11191875   gi_59422      gi_12247041   gi_452637     
  Genotype G   gi_18146661   gi_6983934    gi_19849032                 
  Genotype H   gi_22135696   gi_22135711   gi_22135726                 
  ------------ ------------- ------------- ------------- ------------- ------------

![**Phylogenetic tree map of HBV genome sequencing**. 32 HBV genomes of eight different genotypes were sequenced by HBV genome sequencing, and software MEGA4 was used to analyze these genomes to get the phylogenetic trees of genome sequencing. **Tree Inference**: \[*Method*: Neighbor-Joining; *Phylogeny Test and options*: Bootstrap (1000 replicates; seed = 100000)\]; **Include Sites**: \[*Gaps/Missing Data*: Complete Deletion\]; **Substitution Model**: \[*Model*: Nucleotide: Maximum Composite Likelihood; *Substitutions to Include*: d: Transitions + Transversions; *Pattern among Lineages*: Same (Homogeneous); *Rates among sites*: Uniform rates\]](1755-8794-6-S1-S15-1){#F1}

![**Phylogenetic tree map of HBV S gene sequencing**. 32 HBV genomes of eight different genotypes were sequenced by HBV S gene sequencing, and software MEGA4 was used to analyze these genomes to get the phylogenetic trees of HBV S gene sequencing. **Tree Inference**: \[*Method*: Neighbor-Joining; *Phylogeny Test and options*: Bootstrap (1000 replicates; seed = 100000)\]; **Include Sites**: \[*Gaps/Missing Data*: Complete Deletion; *Codon Positions*: 1st+2nd+3rd\]; **Substitution Model**: \[*Model*: Nucleotide: Maximum Composite Likelihood; *Substitutions to Include*: d: Transitions + Transversions; *Pattern among Lineages*: Same (Homogeneous); *Rates among sites*: Uniform rates\]](1755-8794-6-S1-S15-2){#F2}

![**Phylogenetic tree map of HBV partial S gene sequencing**. 32 HBV genomes of eight different genotypes were sequenced by HBV partial S gene sequencing, and software MEGA4 was used to analyze these genomes to get the phylogenetic trees of HBV partial S gene sequencing. **Tree Inference**: \[*Method*: Neighbor-Joining; *Phylogeny Test and options*: Bootstrap (1000 replicates; seed = 100000)\]; **Include Sites**: \[*Gaps/Missing Data*: Complete Deletion; *Codon Positions*: 1st+2nd+3rd\]; **Substitution Model**: \[*Model*: Nucleotide: Maximum Composite Likelihood; *Substitutions to Include*: d: Transitions + Transversions; *Pattern among Lineages*: Same (Homogeneous); *Rates among sites*: Uniform rates\]](1755-8794-6-S1-S15-3){#F3}

To further evaluate the effect of partial S gene sequencing, 53 HBV genotype A samples; 43 HBV genotype B samples; 50 HBV genotype C samples and 51 HBV genotype D samples were genotyped using partial S gene sequencing and S gene sequencing respectively (shown as Table [2](#T2){ref-type="table"}). Compared the results of these two methods, we found that the results of partial S gene sequencing are consistent with S gene sequencing, except one sample, EU939630. From further recombinant analysis, we found that EU939630 was a C/B recombinant strain (shown as Figure [4](#F4){ref-type="fig"}).

###### 

Sequences for genotyping verification

  Genotype A   AB014370   AB330372   AB453986   AJ627227   AM295800   EU594388
  ------------ ---------- ---------- ---------- ---------- ---------- ----------
  Genotype B   AB014366   AB205119   AB287317   AB287326   EF473977   EU939628
               AB033554   AB205120   AB287318   AB287327   EU595030   EU939629
               AB033555   AB205121   AB287319   AB287328   EU595031   EU939630
               AB115551   AB205122   AB287320   AB287329   EU796066   
               AB117759   AB241117   AB287321   AB365445   EU796067   
               AB195933   AB287314   AB287322   AB368295   EU796068   
               AB195934   AB287315   AB287323   AJ627225   EU796071   
               AB195935   AB287316   AB287325   EF473976   EU939627   
                                                                      
  Genotype C   AB014360   AB014374   AB014384   AB026811   AB033557   AB112065
               AB014362   AB014376   AB014385   AB026812   AB042282   AB112066
               AB014363   AB014377   AB014389   AB026813   AB042283   AB112348
               AB014364   AB014378   AB014391   AB026814   AB042284   AB112471
               AB014365   AB014379   AB014392   AB033550   AB042285   AB112472
               AB014367   AB014380   AB014393   AB033551   AB105172   
               AB014369   AB014381   AB014394   AB033552   AB105173   
               AB014371   AB014382   AB014396   AB033553   AB105174   
               AB014372   AB014383   AB014399   AB033556   AB112063   
                                                                      
  Genotype D   AB033558   AB109475   AB119253   AB188244   AB210822   EU594431
               AB033559   AB109476   AB119254   AB188245   EU594422   EU594432
               AB090268   AB109477   AB119255   AB205126   EU594423   EU594433
               AB090269   AB109478   AB119256   AB205127   EU594424   EU594434
               AB090270   AB109479   AB120308   AB205128   EU594425   EU594435
               AB104709   AB110075   AB126581   AB210818   EU594426   EU594436
               AB104710   AB116266   AB188241   AB210819   EU594427   
               AB104711   AB119251   AB188242   AB210820   EU594428   
               AB104712   AB119252   AB188243   AB210821   EU594430   

![**Genotype and recombinant analysis results of EU939630**. A: Genotype results of 43 HBV genotype B samples using partial S gene sequencing, 42 samples of which had been genotyped correctly except one, EU939630. The arrow indicates EU939630 was genotyped as HBV genotype C by partial S gene sequencing. B: Recombinant analysis result of EU939630. From the recombinant analysis, we found that EU939630 was a C/B recombinant strain.](1755-8794-6-S1-S15-4){#F4}

Sensitivity of partial S gene sequencing
----------------------------------------

147 HBV-positive (HBV copies were more than 500 copies/ml) serum samples were sequenced by partial S gene sequencing, 2 of which could not to be sequenced, so the sensitivity of our partial S gene sequencing was 98.64%.

Application of partial S gene sequencing in recombinant HBV isolates
--------------------------------------------------------------------

Next, we evaluated the application of partial S gene sequencing in HBV recombinant isolates (shown as Figure [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}). 44 recombinant HBV isolates were collected as shown in Table [3](#T3){ref-type="table"}. The genotyping results indicated that there were 38 samples with the same results using partial S gene sequencing and S gene sequencing. Other 6 samples had different genotyping results by these two methods, which were isolated from South Africa (2/6); Thailand (1/6) and Vietnam (3/6) respectively. One sample from South Africa (AF297620) failed to genotype by partial S gene sequencing, as there was a recombinant site in its S region (shown as Figure [7](#F7){ref-type="fig"}) which was analyzed by Simplot software and NCBI Viral genotyping tool.

![**Phylogenetic tree map of HBV recombinant strains using S gene sequencing**. 44 recombinant HBV isolates were collected to draw the phylogenetic tree map of HBV S gene sequencing by the method described above. **Tree Inference**: \[*Method*: Neighbor-Joining; *Phylogeny Test and options*: Bootstrap (1000 replicates; seed = 100000)\]; **Include Sites**: \[*Gaps/Missing Data*: Complete Deletion\]; **Substitution Model**: \[*Model*: Nucleotide: Maximum Composite Likelihood; *Substitutions to Include*: d: Transitions + Transversions; *Pattern among Lineages*: Same (Homogeneous); *Rates among sites*: Uniform rates\]](1755-8794-6-S1-S15-5){#F5}

![**Phylogenetic tree map of HBV recombinant strains using partial S gene sequencing**. 44 recombinant HBV isolates were collected to draw the phylogenetic tree map of HBV partial S gene sequencing by the method described above. **Tree Inference**: \[*Method*: Neighbor-Joining; *Phylogeny Test and options*: Bootstrap (1000 replicates; seed = 100000)\]; **Include Sites**: \[*Gaps/Missing Data*: Complete Deletion\]; **Substitution Model**: \[*Model*: Nucleotide: Maximum Composite Likelihood; *Substitutions to Include*: d: Transitions + Transversions; *Pattern among Lineages*: Same (Homogeneous); *Rates among sites*: Uniform rates\]](1755-8794-6-S1-S15-6){#F6}

###### 

Genotype results of 44 HBV recombinant strains

             Genotyping method   Source                   
  ---------- ------------------- -------- --------------- ----------------------
  EU185780   A                   A        D3/A2           Argentina
  AB194949   A                   A        A (A3/Acmr)/E   Cameroon
  AY817509   D                   D        C/D             China
  AY817510   D                   D        C/D             China
  AY817511   D                   D        C/D             China
  AY817512   D                   D        C/D             China
  AY817513   D                   D        C/D             China
  AY817514   D                   D        C/D             China
  AY817515   D                   D        C/D             China
  AY862860   D                   D        C/D             China
  AY862861   D                   D        C/D             China
  AY862862   D                   D        C/D             China
  AY862863   D                   D        C/D             China
  AY862864   D                   D        C/D             China
  DQ478881   D                   D        C/D             China
  DQ478882   D                   D        C/D             China
  DQ478883   D                   D        C/D             China
  DQ478884   D                   D        C/D             China
  DQ478886   D                   D        C/D             China
  DQ478887   D                   D        C/D             China
  DQ478888   D                   D        C/D             China
  DQ478889   D                   D        C/D             China
  DQ478890   D                   D        C/D             China
  DQ478891   D                   D        C/D             China
  DQ478892   D                   D        C/D             China
  DQ478893   D                   D        C/D             China
  DQ478894   D                   D        C/D             China
  DQ478895   D                   D        C/D             China
  DQ478896   D                   D        C/D             China
  DQ478897   D                   D        C/D             China
  DQ478898   D                   D        C/D             China
  AY057947   C                   C        A/C             China
  AY057948   D                   D        C/D             China
  EF103282   A                   A        A/D             India
  EF103283   A                   A        A/D             India
  EF103284   A                   A        A/D             India
  AB270534   D                   D        C/D             Mongolia:Ulaanbaatar
  AB270535   D                   D        C/D             Mongolia:Ulaanbaatar
  AF297619   D                   A        A/D             South Africa
  AF297620   D                   \-       A/D             South Africa
  DQ078791   C                   G        G/C             Thailand
  AF241407   D                   G        C/A/G/B         Vietnam
  AF241408   D                   G        C/A/G/B         Vietnam
  AF241409   D                   G        C/A/G/B         Vietnam

![**Recombinant analysis results of AF297620**. AF297620 was failed to be genotyped by partial S gene sequencing because it had recombinant sites in partial S gene region.](1755-8794-6-S1-S15-7){#F7}

Drug-resistant mutations analysis
---------------------------------

The part of the S gene we chose for sequencing has many drug-resistant mutant sites, which means it had potential for use in analysis of HBV drug resistant mutation. To evaluate this, we analyzed all possible sites of resistance mutations (V521L; A529V; A529T; T532A; S550I; rtL180M; rtM204V/I; N584T and K589E) of 147 HBV-positive serum samples \[[@B16]\]. Through partial S gene sequencing we detected rtM204V mutation in one sample successfully (shown in Figure [8](#F8){ref-type="fig"}), meaning the partial S gene sequencing could be used in both HBV genotyping and in analysis of HBV drug resistant mutation.

![**Drug resistant mutation analysis by partial S gene sequencing**. Through drug resistant mutation analysis of 147 HBV positive serum samples using partial S gene sequencing, one sample was found to be rtM204V mutation. The arrow indicates the A is replaced by G.](1755-8794-6-S1-S15-8){#F8}

Conclusions
===========

HBV genotyping and the detection of drug resistance mutations are important for monitoring the treatment of chronic hepatitis B, but there are a limited number of methods for the simultaneous detection of HBV genotypes and drug resistance mutations \[[@B11],[@B13]\]. We have established a partial S gene sequencing method to genotype HBV isolates as well as detect drug resistance mutations at the same time. To testify the sensitivity of our partial S gene sequencing, 147 clinical serum samples were used, and 145 samples could be sequenced successfully by this assay, with a sensitivity of 98.64%.

The part of S gene we chose for sequencing has many drug-resistant mutant sites, and we detected all possible mutant sites in this region of 145 samples and found the rtM204V mutation in one sample. That means the partial S gene sequencing could be used in analysis of HBV drug resistant mutation.

To evaluate the potential of partial S gene sequencing for use in HBV genotyping, the phylogenetic tree analysis was used. From the phylogenetic tree mapping, we found that the partial S gene sequencing had nearly the same phylogenetic tree map to that of the S gene sequencing (shown as Figure [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). This means partial S gene sequencing has the possibility to be used as a promising method in HBV genotyping. To further demonstrate this, 197 HBV positive serum samples of four different genotypes (A, B, C, and D) were genotyped using partial S gene sequencing and S gene sequencing respectively (Table [2](#T2){ref-type="table"}). Although at least eight HBV genotypes have been reported, the major HBV genotypes in China are B and C \[[@B12],[@B15]\]. Genotypes A and D are found in a very small proportion of Chinese patients, and genotypes E, F, G, and H have not been reported in China. As a result, we only evaluated the performance of partial S gene sequencing assay for genotypes A, B, C, and D in our study. We found the results of partial S gene sequencing were consistent with S gene sequencing, except one sample, EU939630, which was proved to be a C/B recombinant strain. From this, we have proved that this assay could specifically detect mutant and wild-type HBV in clinical serum samples.

Considering that the recombinant strain might disturb genotyping effect, we evaluated the application of partial S gene sequencing in 44 HBV recombinant isolates (Table [3](#T3){ref-type="table"}). 43 samples could be genotyped correctly by partial S gene sequencing method, meanwhile, S gene sequencing genotyped 41 samples successfully. That means partial S gene sequencing had the potential to take the place of S gene sequencing in the field of HBV genotyping.

Based on these findings, we could draw the conclusion that the partial S gene sequencing assay developed in this study could be applied in HBV genotyping and drug resistant mutation detection. It might be an ideal choice for HBV genotyping for it is simpler and more convenient than traditional S gene sequencing while it has nearly the same sensitivity and specificity as S gene sequencing.

Methods
=======

Serum samples
-------------

Serum samples are collected from four hospitals: the Second People Hospital of Guangdong Province, the First Affiliated Hospital of Guangzhou Medical College, Guangzhou Overseas Chinese Hospital, and Guangzhou Huadu Ren-Ai Hospital. All these serum samples were collected in compliance with the Helsinki Declaration, and all the patients who provided serum samples were voluntary. This study was approved by the Institutional Review Board of Wuhan University. All specimens were sampled from sterile blood vessels (excluding anticoagulant) and stored at -20°C.

Sequencing
----------

HBV DNA was isolated from serum (QIAamp DNA Blood Mini Kit, QIAGEN, Hilden, Germany) according to the kit instructions. A product of 491 base pairs of partial S gene was amplified with the primers F (sense, 5\'- TCGCTGGATGTGTCTGCGGCGTTTTAT-3\') and R (antisense, 5\'- ACCCCATCTTTTTGTTTTGTTAGG-3\') using a PCR protocol as follows: 12 min at 95°C, 35 cycles of 1 min at 94°C, 1 min at 52°C, 1 min at 72°C, and a final elongation step of 7 min at 72°C, using the AmpliTaq Gold amplification system.

Phylogenetic tree analysis
--------------------------

To testify the feasibility of the partial S gene sequencing used for HBV genotyping, 32 different genotypes of the HBV (<http://lancelot.otago.ac.nz>) genome sequence were chosen as the reference sequences (shown in Table [1](#T1){ref-type="table"}). Three different DNA sequencing methods were used to genotype serum samples for phylogenetic tree mapping: whole genome sequencing, S gene sequencing and partial S gene sequencing.
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